Chaetochromin, also known as 4548-G05, is an orally active, small-molecule, selective agonist of the insulin receptor.[1] It has potent and long-lasting antidiabetic activity in vivo in mice.[1] The drug may represent a novel potential therapeutic agent for the treatment of diabetes which is more convenient and tolerable to administer than injected insulin.[1] It was discovered in 1981 in Chaetomium gracile fungi,[2] and its interaction with the insulin receptor was identified in 2014.[1]
Clinical data | |
---|---|
Other names | 4548-G05 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C30H26O10 |
Molar mass | 546.528 g·mol−1 |
3D model (JSmol) | |
| |
|
Stereochemistry
editChaetochromin A and B are stereoisomers of this structure, while chaetochromin C and D are related but different compounds.[3] It is not known whether the insulin mimetic effect was found in chaetochromin A or B, or in a mixture.[1]
See also
editReferences
edit- ^ a b c d e Qiang G, Xue S, Yang JJ, Du G, Pang X, Li X, et al. (April 2014). "Identification of a small molecular insulin receptor agonist with potent antidiabetes activity". Diabetes. 63 (4): 1394–1409. doi:10.2337/db13-0334. PMC 3964510. PMID 24651808.
- ^ Sekita S, Yoshihira K, Natori S, Udagawa S, Muroi T, Sugiyama Y, et al. (August 1981). "Mycotoxin production by Chaetomium spp. and related fungi". Canadian Journal of Microbiology. 27 (8): 766–772. doi:10.1139/m81-119. PMID 7296410.
- ^ "Chaetochromin". PubChem. U.S. National Library of Medicine.